idya-10q_20190930.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2019

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934

For the transition period from                      to                     

Commission File Number: 001-38915

 

IDEAYA Biosciences, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

47-4268251

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

 

7000 Shoreline Court, Suite 350

South San Francisco, California

 

94080

(Address of principal executive offices)

 

(Zip Code)

 

(650) 443-6209

(telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

 

IDYA

 

Nasdaq Global Select Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

 

Accelerated filer

Non-accelerated filer

 

 

Smaller reporting company

 

 

 

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

As of November 1, 2019, the registrant had 20,331,095 shares of common stock, $0.0001 par value per share, outstanding.

 

 

 

 


FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts contained in this Form 10-Q, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations and future results of anticipated products, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of risks, uncertainties and assumptions described under the sections in this Quarterly Report on Form 10-Q entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in this Quarterly Report on Form 10-Q. These forward-looking statements are subject to numerous risks, including, without limitation, the following:

our status as a development-stage company and our expectation to incur losses in the future;

our future capital needs and our need to raise additional funds;

our ability to build a pipeline of product candidates and develop and commercialize drugs;

our unproven approach to therapeutic intervention;

our ability to enroll patients and volunteers in clinical trials, timely and successfully complete those trials and receive necessary regulatory approvals;

our ability to establish our own manufacturing facilities and to receive or manufacture sufficient quantities of our product candidates;

our ability to protect and enforce our intellectual property rights;

federal, state, and foreign regulatory requirements, including FDA regulation of our product candidates;

the timing of clinical trials and the likelihood of regulatory filings and approvals;

our ability to obtain and retain key executives and attract and retain qualified personnel; and

our ability to successfully manage our growth.

Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not occur or be achieved, and actual results could differ materially from those projected in the forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

1


IDEAYA Biosciences, Inc.

Form 10-Q for Quarterly Period Ended September 30, 2019

Table of Contents

 

PART I—FINANCIAL INFORMATION

3

Item 1. Financial Statements (Unaudited)

3

Condensed Balance Sheets

3

Condensed Statements of Operations and Comprehensive Loss

4

Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit)

5

Condensed Statements of Cash Flows

7

Notes to Condensed Financial Statements (Unaudited)

8

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

23

Item 3. Quantitative and Qualitative Disclosures About Market Risk

33

Item 4. Controls and Procedures

33

PART II—OTHER INFORMATION

34

Item 1. Legal Proceedings

34

Item 1A. Risk Factors

34

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

90

Item 3. Defaults Upon Senior Securities

91

Item 4. Mine Safety Disclosures

91

Item 5. Other information

91

Item 6. Exhibits

92

SIGNATURES

94

 

2


PART I—FINANCIAL INFORMATION

Item 1. Financial Statements (UNAUDITED).

IDEAYA Biosciences, Inc.

Condensed Balance Sheets

(in thousands, except share and per share amounts)

(Unaudited)

 

 

 

September 30,

 

 

December 31,

 

 

 

2019

 

 

2018

 

Assets

 

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

38,848

 

 

$

20,505

 

Short-term marketable securities

 

 

70,508

 

 

 

69,456

 

Prepaid expenses and other current assets

 

 

2,805

 

 

 

706

 

Total current assets

 

 

112,161

 

 

 

90,667

 

Restricted cash

 

 

106

 

 

 

106

 

Property and equipment, net

 

 

4,767

 

 

 

5,152

 

Deferred offering costs

 

 

 

 

 

570

 

Right-of-use assets

 

 

5,279

 

 

 

 

Other non-current assets

 

 

18

 

 

 

46

 

Total assets

 

$

122,331

 

 

$

96,541

 

Liabilities, Redeemable Convertible Preferred Stock and Stockholders’

   Equity (Deficit)

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

Accounts payable

 

$

763

 

 

$

1,417

 

Accrued liabilities

 

 

3,992

 

 

 

3,583

 

Deferred rent

 

 

 

 

 

299

 

Lease liabilities

 

 

1,116

 

 

 

 

Other current liabilities

 

 

76

 

 

 

114

 

Total current liabilities

 

 

5,947

 

 

 

5,413

 

Deferred rent

 

 

 

 

 

1,572

 

Long-term lease liabilities

 

 

5,926

 

 

 

 

Other non-current liabilities

 

 

52

 

 

 

113

 

Total liabilities

 

 

11,925

 

 

 

7,098

 

Commitments and contingencies (Note 5)

 

 

 

 

 

 

 

 

Series A redeemable convertible preferred stock, $0.0001 par value, no shares

   authorized as of September 30, 2019 and 59,433,105 shares authorized as of

   December 31, 2018; no shares issued and outstanding as of September 30, 2019 and

   5,794,727 shares issued and outstanding as of December 31, 2018; liquidation

   value of $0 as of September 30, 2019 and $47,178 as of December 31, 2018

 

 

 

 

 

40,735

 

Series B redeemable convertible preferred stock, $0.0001 par value, no shares

   authorized as of September 30, 2019 and 75,500,000 shares authorized as of

   December 31, 2018; no shares issued and outstanding as of September 30, 2019 and

   7,345,067 shares issued and outstanding as of December 31, 2018; liquidation

   value of $0 as of September 30, 2019 and $97,520 as of December 31, 2018

 

 

 

 

 

97,656

 

Stockholder’s equity (deficit)

 

 

 

 

 

 

 

 

Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of September 30,

   2019 and no shares authorized as of December 31, 2018; no shares issued

   and outstanding as of September 30, 2019 and December 31, 2018

 

 

 

 

 

 

Common stock, $0.0001 par value, 300,000,000 shares authorized as of

   September 30, 2019 and 170,800,000 shares authorized as of December 31, 2018;

   20,328,242 and 1,335,690 shares issued and outstanding as of September 30, 2019

   and December 31, 2018

 

 

2

 

 

 

 

Additional paid-in capital

 

 

192,036

 

 

 

1,599

 

Accumulated other comprehensive income (loss)

 

 

78

 

 

 

(31

)

Accumulated deficit

 

 

(81,710

)

 

 

(50,516

)

Total stockholders’ equity (deficit)

 

 

110,406

 

 

 

(48,948

)

Total liabilities, redeemable convertible preferred stock and stockholders’

   equity (deficit)

 

$

122,331

 

 

$

96,541

 

 

The accompanying notes are an integral part of these condensed financial statements.  

3


IDEAYA Biosciences, Inc.

Condensed Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

(Unaudited)

 

 

 

Three Months Ended

September 30,

 

 

Nine Months Ended

September 30,

 

 

 

2019

 

 

2018

 

 

2019

 

 

2018

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

8,923

 

 

$

12,538

 

 

$

25,778

 

 

$

24,172

 

General and administrative

 

 

2,700

 

 

 

1,088

 

 

 

7,174

 

 

 

3,112

 

Total operating expenses

 

 

11,623

 

 

 

13,626

 

 

 

32,952

 

 

 

27,284

 

Loss from operations

 

 

(11,623

)

 

 

(13,626

)

 

 

(32,952

)

 

 

(27,284

)

Interest income

 

 

654

 

 

 

573

 

 

 

1,752

 

 

 

1,423

 

Other income (expense), net

 

 

 

 

 

1

 

 

 

6

 

 

 

77

 

Net loss

 

$

(10,969

)

 

$

(13,052

)

 

$

(31,194

)

 

$

(25,784

)

Change in unrealized gains (losses) on marketable

   securities

 

 

41

 

 

 

16

 

 

 

109

 

 

 

(16

)

Comprehensive loss

 

$

(10,928

)

 

$

(13,036

)

 

$

(31,085

)

 

$

(25,800

)

Net loss per share attributable to common stockholders,

    basic and diluted

 

$

(0.54

)

 

$

(13.06

)

 

$

(3.15

)

 

$

(27.94

)

Weighted average number of shares outstanding, basic

    and diluted

 

 

20,158,223

 

 

 

999,369

 

 

 

9,895,574

 

 

 

922,664

 

 

The accompanying notes are an integral part of these condensed financial statements.

 

4


IDEAYA Biosciences, Inc.

Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit)

(in thousands, except share amounts)

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

Redeemable Convertible

 

 

 

 

 

 

 

 

 

 

Additional

 

 

Other

 

 

 

 

 

 

Total

 

 

 

Preferred Stock

 

 

Common Stock

 

 

Paid-In

 

 

Comprehensive

 

 

Accumulated

 

 

Stockholders'

 

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Income (Loss)

 

 

Deficit

 

 

Deficit

 

Balances as of June 30, 2019

 

 

 

 

$

 

 

 

20,268,103

 

 

$

2

 

 

$

191,310

 

 

$

37

 

 

$

(70,741

)

 

$

120,608

 

Issuance of common stock upon exercise of stock options

 

 

 

 

 

 

 

 

62,501

 

 

 

 

 

 

190

 

 

 

 

 

 

 

 

 

190

 

Repurchase of early exercised shares

 

 

 

 

 

 

 

 

(2,362

)

 

 

 

 

 

(2

)

 

 

 

 

 

 

 

 

(2

)

Vesting of early exercised common stock options and restricted stock

 

 

 

 

 

 

 

 

 

 

 

 

 

 

20

 

 

 

 

 

 

 

 

 

20

 

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

518

 

 

 

 

 

 

 

 

 

518

 

Other comprehensive income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

41

 

 

 

 

 

 

41

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(10,969

)

 

 

(10,969

)

Balances as of September 30, 2019

 

 

 

 

$

 

 

 

20,328,242

 

 

$

2

 

 

$

192,036

 

 

$

78

 

 

$

(81,710

)

 

$

110,406

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances as of June 30, 2018

 

 

12,876,179

 

 

$

134,579

 

 

 

1,331,316

 

 

$

 

 

$

886

 

 

$

(33

)

 

$

(28,902

)

 

$

(28,049

)

Issuance of Series B redeemable convertible preferred stock

    pursuant to license agreement

 

 

263,615

 

 

 

3,812

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock upon exercise of stock options

 

 

 

 

 

 

 

 

13,656

 

 

 

 

 

 

23

 

 

 

 

 

 

 

 

 

23

 

Early exercised common stock options

 

 

 

 

 

 

 

 

5,338

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Repurchase of early exercised shares

 

 

 

 

 

 

 

 

(7,913

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Vesting of early exercised common stock options and restricted stock

 

 

 

 

 

 

 

 

 

 

 

 

 

 

38

 

 

 

 

 

 

 

 

 

38

 

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

287

 

 

 

 

 

 

 

 

 

287

 

Other comprehensive income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

16

 

 

 

 

 

 

16

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(13,052

)

 

 

(13,052

)

Balances as of September 30, 2018

 

 

13,139,794

 

 

$

138,391

 

 

 

1,342,397

 

 

$

 

 

$

1,234

 

 

$

(17

)

 

$

(41,954

)

 

$

(40,737

)

 

The accompanying notes are an integral part of these condensed financial statements.


5


 

IDEAYA Biosciences, Inc.

Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit)(Continued)

(in thousands, except share amounts)

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

Redeemable Convertible

 

 

 

 

 

 

 

 

 

 

Additional

 

 

Other

 

 

 

 

 

 

Total

 

 

 

Preferred Stock

 

 

Common Stock

 

 

Paid-In

 

 

Comprehensive

 

 

Accumulated

 

 

Stockholders'

 

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Income (Loss)

 

 

Deficit

 

 

Deficit

 

Balances as of December 31, 2018

 

 

13,139,794

 

 

$

138,391

 

 

 

1,335,690

 

 

$

 

 

$

1,599

 

 

$

(31

)

 

$

(50,516

)

 

$

(48,948

)

Conversion of redeemable convertible preferred stock into common

    stock

 

 

(13,139,794

)

 

 

(138,391

)

 

 

13,139,794

 

 

 

1

 

 

 

138,390

 

 

 

 

 

 

 

 

 

138,391

 

Issuance of common stock upon initial public offering, net of

    issuance cost

 

 

 

 

 

 

 

 

5,750,000

 

 

 

1

 

 

 

50,246

 

 

 

 

 

 

 

 

 

50,247

 

Issuance of common stock upon exercise of stock options

 

 

 

 

 

 

 

 

114,890

 

 

 

 

 

 

261

 

 

 

 

 

 

 

 

 

261

 

Early exercised common stock options

 

 

 

 

 

 

 

 

2,112

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Repurchase of early exercised shares

 

 

 

 

 

 

 

 

(14,244

)

 

 

 

 

 

(2

)

 

 

 

 

 

 

 

 

(2

)

Vesting of early exercised common stock options and restricted stock

 

 

 

 

 

 

 

 

 

 

 

 

 

 

93

 

 

 

 

 

 

 

 

 

93

 

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1,449

 

 

 

 

 

 

 

 

 

1,449

 

Other comprehensive income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

109

 

 

 

 

 

 

109

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(31,194

)

 

 

(31,194

)

Balances as of September 30, 3019

 

 

 

 

$

 

 

 

20,328,242

 

 

$

2

 

 

$

192,036

 

 

$

78

 

 

$

(81,710

)

 

$

110,406

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances as of December 31, 2017

 

 

4,379,916

 

 

$

26,084

 

 

 

1,263,416

 

 

$

 

 

$

432

 

 

$

(1

)

 

$

(16,170

)

 

$

(15,739

)

Issuance of Series A redeemable convertible preferred stock, net of

    issuance costs of $5, adjusted for the redeemable convertible

    preferred stock liability of $3,137

 

 

1,414,811

 

 

 

14,651

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of Series B redeemable convertible preferred stock, net of

    issuance costs of $176

 

 

7,081,452

 

 

 

93,844

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of Series B redeemable convertible preferred stock

    pursuant to license agreement

 

 

263,615

 

 

 

3,812

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock upon exercise of stock options

 

 

 

 

 

 

 

 

16,311

 

 

 

 

 

 

25

 

 

 

 

 

 

 

 

 

25

 

Early exercised common stock options

 

 

 

 

 

 

 

 

70,583

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Repurchase of early exercised shares

 

 

 

 

 

 

 

 

 

 

(7,913

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Vesting of early exercised common stock options and restricted stock

 

 

 

 

 

 

 

 

 

 

 

 

 

 

152

 

 

 

 

 

 

 

 

 

152

 

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

625

 

 

 

 

 

 

 

 

 

625

 

Other comprehensive loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(16

)

 

 

 

 

 

(16

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(25,784

)

 

 

(25,784

)

Balances as of September 30, 2018

 

 

13,139,794

 

 

$

138,391

 

 

 

1,342,397

 

 

$

 

 

$

1,234

 

 

$

(17

)

 

$

(41,954

)

 

$

(40,737

)

 

The accompanying notes are an integral part of these condensed financial statements.

 

6


IDEAYA Biosciences, Inc.

Condensed Statements of Cash Flows

(in thousands)

(Unaudited)

 

 

 

Nine Months Ended September 30,

 

 

 

2019

 

 

2018

 

Cash flows from operating activities

 

 

 

 

 

 

 

 

Net loss

 

$

(31,194

)

 

$

(25,784

)

Adjustments to reconcile net loss to net cash used in operating activities

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

915

 

 

 

623

 

Net amortization of premiums and discounts on marketable securities

 

 

(451

)

 

 

(526

)

Stock-based compensation

 

 

1,449

 

 

 

625

 

Issuance of Series B redeemable convertible preferred stock pursuant

    to license agreement

 

 

 

 

 

3,812

 

Change in fair value of redeemable convertible preferred stock liability

 

 

 

 

 

(70

)

Landlord contributions for leasehold improvements

 

 

 

 

 

129

 

Loss (gain) on sale of property and equipment

 

 

14

 

 

 

(41

)

Gain on sales of marketable securities

 

 

(7

)

 

 

(11

)

Changes in assets and liabilities

 

 

 

 

 

 

 

 

Prepaid expenses and other assets

 

 

(2,071

)

 

 

(109

)

Right-of-use assets

 

 

870

 

 

 

 

Accounts payable

 

 

(153

)

 

 

352

 

Accrued and other liabilities

 

 

1,000

 

 

 

917

 

Deferred rent

 

 

 

 

 

(60

)

Lease liabilities

 

 

(979

)

 

 

 

Net cash used in operating activities

 

 

(30,607

)

 

 

(20,143

)

Cash flows from investing activities

 

 

 

 

 

 

 

 

Purchases of property and equipment, net

 

 

(1,137

)

 

 

(1,400

)

Purchases of marketable securities

 

 

(86,117

)

 

 

(112,155

)

Maturities of marketable securities

 

 

67,538

 

 

 

40,800

 

Sales of marketable securities

 

 

18,094

 

 

 

3,000

 

Net cash used in investing activities

 

 

(1,622

)

 

 

(69,755

)

Cash flows from financing activities

 

 

 

 

 

 

 

 

Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs

 

 

 

 

 

105,358

 

Proceeds from issuance of common stock in initial public offering, net of issuance costs